CareLit · DOI-Nachweis · Klinische Pädiatrie
Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients
DOI 10.1055/s-0034-1371153
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Janku, I Garrido-Laguna, V Velez-Bravo, G Falchook, V Subbiah, D Hong, Y Oki, J Westin, C Nunez, L Fayad, L Kwak, S Neelapu, E Shpall, J Wheler, W Lang, B Salhia, F Meric-Bernstam, R Kurzrock, M Fanale
ZeitschriftKlinische Pädiatrie
Ausgabe03/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Preclinical models have suggested that HDAC and mTOR inhibitors have synergistic antineoplastic activity in Hodgkin lymphoma and other cancers by reducing the activity of AKT, mTOR and HDAC. Methods: We designed a phase I study to determine the safety of the mTOR inhibitor sirolimus (1 mg – 5 mg PO daily q 28 days) and HDAC inhibitor vorinostat (100 mg – 400 mg PO daily q 28 days) in advanced cancers wit…
Zitieren
Zitierempfehlung
F Janku, I Garrido-Laguna, V Velez-Bravo, G Falchook, V Subbiah, D Hong, Y Oki, J Westin, C Nunez, L Fayad, L Kwak, S Neelapu, E Shpall, J Wheler, W Lang, B Salhia, F Meric-Bernstam, R Kurzrock, M Fanale (2014) Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Klinische Pädiatrie (03). https://doi.org/10.1055/s-0034-1371153
Mit CareLit weiterarbeiten